• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Past Event

OHE Lunchtime Seminar: Health Technology Assessment Scientific and Outcomes Advice on Medicinal Drug Development

OHE lunchtime seminar with Leeza Osipenko (NICE Scientific Advice), Nancy Delvin and François Maignen (OHE) Health Technology Assessment (HTA) scientific advice (SA) was created by the National Institute for Health and Care Excellence in 2009. More recent initiatives have sought…

Date

04/10/16 11:00 pm

OHE lunchtime seminar with Leeza Osipenko (NICE Scientific Advice), Nancy Delvin and François Maignen (OHE)

Health Technology Assessment (HTA) scientific advice (SA) was created by the National Institute for Health and Care Excellence in 2009. More recent initiatives have sought to coordinate HTA SA across Europe and promote the integration of HTA SA with the advice provided by regulatory authorities (Medicines and Healthcare products Regulatory Agency, MHRA, and European Medicines Agency, EMA). Despite these efforts HTA SA is not routinely integrated into the clinical development of new medicines and it faces new challenges with the development of advanced therapy medicinal products, stratified medicines and medicines used in orphan diseases.  The role of outcomes advice in HTA is not well understood, yet is equally important.

In this lunchtime seminar, the panellists will give their perspectives on the influence of HTA scientific and outcomes advice on both the clinical development of new medicines and evidence generation to support reimbursement. Their presentations will cover:

  • The importance of developing a value proposition early in clinical development;
  • The different types of scientific advice procedures;
  • The timing of scientific and outcomes advice in the clinical development of medicines;
  • The integration of HTA with regulatory scientific advice;
  • Issues associated with new approaches to drug development (adaptive licensing, real world evidence and advanced therapies);
  • Future developments in HTA scientific advice;
  • Issues specific to outcomes advice.

The panel will be chaired by Paula Lorgelly, Deputy Director, OHE, and will include three presenters, all of whom are involved in issues directly relevant to HTA SA:

  • Dr Leeza Osipenko, Head of Scientific Advice, NICE
  • Professor Nancy Devlin, Director of Research, OHE
  • Dr François Maignen, Head of Operational Research and Data Analytics, OHE

Dr Leeza Osipenko works closely with EMA, MHRA, European HTA agencies and EUnetHTA. She chairs most of the national, international and parallel scientific advice meetings, signs off all key deliverables produced by the team and leads on business development activities via frequent public speaking engagements. Dr Osipenko holds an Honorary Fellow post at the University of Warwick Medical School and represents NICE as a Chief Analyst at the Department of Health Analytical Directors of Arm’s Length Bodies (ALBs) group. She has completed a BA in Economics & International Affairs, MSc in Technology Management and a PhD in Systems Engineering. As a Senior Research Fellow at University of Warwick, she conducted an economic evaluation of non-invasive prenatal diagnostic tests. In 2010, she became a Principal Economist at a London-based public sector consultancy, Optimity Matrix, where she led on projects for NICE, the European Commission and other public sector organisations.

Prof Nancy Devlin’s principal areas of research expertise are the measurement and valuation of patient reported health outcomes; the cost effectiveness thresholds used in making judgments about value for money in health care; use of MCDA in health care decision making; priority setting in health care; and measuring the production, performance and efficiency of hospitals. Nancy holds honorary chairs at the School of Health and Related Research at the University of Sheffield; and in the Economics Department at City University, London. She is past-President of the EuroQol Group, a European-based international network of researchers that developed the EQ-5D, and is an elected member of the Board of Directors, ISPOR. Prior to joining OHE in 2009, Nancy was a Professor of Economics at City University, where she was Head of the Economics Department and Acting Dean of Social Sciences. She has over 30 years of experience as a researcher and as an advisor to health care organisations, both in the public and private sectors in the UK and internationally.

Dr François Maignen is a pharmacist and a statistician. His areas of expertise include the clinical development and supervision of medicines. His expertise covers both the clinical development of medicines and cost-effectiveness evaluations. He has knowledge and expertise in the methodological aspects and difficulties of drug development, post-authorisation studies (observational and pharmacoepidemiology studies) and health technology appraisals. Prior to joining the OHE in 2016 François worked for NICE on scientific advice. Francois was giving advice to pharmaceutical companies on their clinical development plans particularly on phase 3 main pivotal efficacy studies. He has also developed the NICE scientific advice database. Prior to NICE Francois worked for the EMA for 15 years. His activities covered both pre- (registration of centrally authorised products in oncology, cardiology and metabolic diseases including orphan drugs) and post-authorisation procedures (including urgent safety-related), support to the scientific committees (CHMP, PRAC), EU legislation and guidelines (biosimilar and signal management in the EU), signal detection and the implementation of the European pharmacovigilance database (EudraVigilance).

If you would like to attend this seminar please reply to Kerry Sheppard.  Kerry will provide confirmation once she has received your request.

Related Events

Tekado
  • Past Event
  • Commissioned Webinar
  • August 2023

Partnerships for Health System Innovation and Improvement

Read more
Eco-conscious car journeying through forest landscape, Earth pla
  • Past Event
  • Annual Lecture
  • July 2023

OHE Annual Lecture 2023 | The ECO-nomics of Health in a Shifting Climate: Fostering Well-being, Sustainable Livelihoods, and a Greener Future

Read more
cape-town-2575437
  • Past Event
  • July 2023

OHE at IHEA 2023

Read more
sustainaibiity
  • Past Event
  • OHE Webinar
  • Sponsored Webinar
  • May 2023

Supporting Sustainability in the Era of Green Pharmaceuticals

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!